ACE2 and prostate carcinoma: Preclinical studies on prostate cancer have demonstrated that while the pharmacological inhibition of androgen receptor decreases the expression of TMPRSS2, in parallel it induces the expression of ACE2, increasing the risk of SARS-CoV-2 infection [10].